Cargando…
Current status of potential therapeutic candidates for the COVID-19 crisis
As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175848/ https://www.ncbi.nlm.nih.gov/pubmed/32334062 http://dx.doi.org/10.1016/j.bbi.2020.04.046 |
_version_ | 1783524910249803776 |
---|---|
author | Zhang, Jiancheng Xie, Bing Hashimoto, Kenji |
author_facet | Zhang, Jiancheng Xie, Bing Hashimoto, Kenji |
author_sort | Zhang, Jiancheng |
collection | PubMed |
description | As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness. |
format | Online Article Text |
id | pubmed-7175848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71758482020-04-22 Current status of potential therapeutic candidates for the COVID-19 crisis Zhang, Jiancheng Xie, Bing Hashimoto, Kenji Brain Behav Immun Article As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness. Elsevier Inc. 2020-07 2020-04-22 /pmc/articles/PMC7175848/ /pubmed/32334062 http://dx.doi.org/10.1016/j.bbi.2020.04.046 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Zhang, Jiancheng Xie, Bing Hashimoto, Kenji Current status of potential therapeutic candidates for the COVID-19 crisis |
title | Current status of potential therapeutic candidates for the COVID-19 crisis |
title_full | Current status of potential therapeutic candidates for the COVID-19 crisis |
title_fullStr | Current status of potential therapeutic candidates for the COVID-19 crisis |
title_full_unstemmed | Current status of potential therapeutic candidates for the COVID-19 crisis |
title_short | Current status of potential therapeutic candidates for the COVID-19 crisis |
title_sort | current status of potential therapeutic candidates for the covid-19 crisis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175848/ https://www.ncbi.nlm.nih.gov/pubmed/32334062 http://dx.doi.org/10.1016/j.bbi.2020.04.046 |
work_keys_str_mv | AT zhangjiancheng currentstatusofpotentialtherapeuticcandidatesforthecovid19crisis AT xiebing currentstatusofpotentialtherapeuticcandidatesforthecovid19crisis AT hashimotokenji currentstatusofpotentialtherapeuticcandidatesforthecovid19crisis |